Intrexon Corp  

(Public, NYSE:XON)   Watch this stock  
Find more results for Steve Turley
-0.53 (-2.63%)
Apr 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 19.08 - 20.22
52 week 17.52 - 38.50
Open 20.22
Vol / Avg. 511,895.00/929,621.00
Mkt cap 1.92B
P/E     -
Div/yield     -
EPS -1.38
Shares 97.79M
Beta     -
Inst. own 81%
Mar 12, 2014
Intrexon Corp at Barclays Healthcare Conference
Feb 10, 2014
Intrexon Corp at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -186.35% -169.62%
Operating margin -258.02% -244.20%
EBITD margin - -213.88%
Return on average assets -10.88% -12.98%
Return on average equity -13.16% -254.03%
Employees 208 -
CDP Score - -


United States - Map
+1-301-5569809 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intrexon Corporation, is engaged in the business of synthetic biology. Using the Company�s suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. In March 2014, the Company acquired Medistem, Inc. In March 2014, Intrexon Corp acquired laboratory operations in Budapest, Hungary from Codexis, Inc.

Officers and directors

Randal J. Kirk Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Rick Sterling Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Krish S. Krishnan Chief Operating Officer
Age: 48
Bio & Compensation  - Reuters
Samuel E. Broder Ph.D, M.D. Executive Vice President - Scientific and Public Affairs
Age: 63
Bio & Compensation  - Reuters
Thomas Richard Kasser Ph.D. Senior Vice President - Food Sector
Age: 57
Bio & Compensation  - Reuters
Suma M. Krishnan Senior Vice President - Regulatory Affairs
Age: 48
Bio & Compensation  - Reuters
Robert F. Walsh III Senior Vice President - Energy and Chemicals Sector, President - Industrial Products Division
Age: 55
Bio & Compensation  - Reuters
Darryl Webster Senior Vice President - Intellectual Property
Age: 53
Bio & Compensation  - Reuters
Dana Di Ferdinando Chief Information Officer
Bio & Compensation  - Reuters
Thomas D. Reed Ph.D. Chief Science Officer
Age: 47
Bio & Compensation  - Reuters